Production (Stage)
Sagimet Biosciences Inc.
SGMT
$3.55
$0.051.43%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 29.01% | 4.44% | -5.45% | 79.59% | 53.91% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 126.56% | 92.21% | 78.82% | 50.05% | 29.61% |
| Operating Income | -126.56% | -92.21% | -126.81% | -50.05% | -29.61% |
| Income Before Tax | -174.19% | -98.76% | -130.11% | -19.65% | -0.64% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -174.19% | -98.76% | -130.11% | -19.65% | -0.64% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -174.19% | -98.76% | -130.11% | -19.65% | -0.64% |
| EBIT | -126.56% | -92.21% | -126.81% | -50.05% | -29.61% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -147.31% | -44.76% | -30.24% | 99.29% | 99.36% |
| Normalized Basic EPS | -147.23% | -44.73% | -30.29% | 99.29% | 99.36% |
| EPS Diluted | -147.31% | -44.76% | -30.24% | 99.29% | 99.36% |
| Normalized Diluted EPS | -147.23% | -44.73% | -30.29% | 99.29% | 99.36% |
| Average Basic Shares Outstanding | 10.87% | 37.31% | 76.66% | 16,741.11% | 15,588.49% |
| Average Diluted Shares Outstanding | 10.87% | 37.31% | 76.66% | 16,741.11% | 15,588.49% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |